5 CHAPTER 5 108 Supplementary information Table S1 https://ars.els-cdn.com/content/image/1-s2.0-S2452073X22000290-mmc2.docx Figure S1 https://ars.els-cdn.com/content/image/1-s2.0-S2452073X22000290-mmc1.pdf Author’s contributions: Aster V.E. Harder: Conceptualization, Data curation, Formal analysis, Investigation, Writing original draft, Methodology, Project Administration. Gerrit L.J. Onderwater: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project Administration, Writing – Review & Editing. Robin M. van Dongen: Conceptualization, Investigation, Writing – Review & Editing Marieke Heijink: Methodology, Validation, Writing – Review & Editing. Erik W. van Zwet: Formal analysis, Methodology, Writing – Review & Editing. Martin Giera: Conceptualization, Resources, Validation, Writing – Review & Editing. Arn M.J.M. van den Maagdenberg: Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing. Gisela M. Terwindt: Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing. Conflict of interests: G.M.T. reports consultancy support from Novartis, Allergan/Abbvie, Lilly, Teva, Lundbeck and independent support from Dutch Research Council, the Dutch Heart & Brain Foundations, IRRF and Dioraphte. A.M.J.M.v.d.M reports research support from Schedule 1 Therapeutics, AbbVie and Praxis Precision Medicine. The remaining authors have no conflicts of interest to declare. Acknowledgements: We greatly acknowledge the subjects who participated in this study. Funding information: This study was supported by the Netherlands Organization for Health Research and Development (ZonMw) (Clinical Fellowship 90700217 and VIDI grant 917.11.31 to G.M.T.), and European Community (EC) FP7-EUROHEADPAIN (602633 to A.M.J.M.v.d.M.). Data availability: Data not published within the article is available from the corresponding author upon reasonable request.
RkJQdWJsaXNoZXIy MTk4NDMw